HomeCompareQUOT vs JNJ

QUOT vs JNJ: Dividend Comparison 2026

QUOT yields 50.06% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QUOT wins by $365.0K in total portfolio value
10 years
QUOT
QUOT
● Live price
50.06%
Share price
$4.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$395.3K
Annual income
$80,188.15
Full QUOT calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — QUOT vs JNJ

📍 QUOT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQUOTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QUOT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QUOT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QUOT
Annual income on $10K today (after 15% tax)
$4,255.32/yr
After 10yr DRIP, annual income (after tax)
$68,159.93/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, QUOT beats the other by $64,173.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QUOT + JNJ for your $10,000?

QUOT: 50%JNJ: 50%
100% JNJ50/50100% QUOT
Portfolio after 10yr
$212.8K
Annual income
$42,438.77/yr
Blended yield
19.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

QUOT
No analyst data
Altman Z
-0.4
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QUOT buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQUOTJNJ
Forward yield50.06%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$395.3K$30.3K
Annual income after 10y$80,188.15$4,689.40
Total dividends collected$315.5K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QUOT vs JNJ ($10,000, DRIP)

YearQUOT PortfolioQUOT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$15,706$5,006.26$10,592$272.30+$5.1KQUOT
2$24,154$7,348.56$11,289$357.73+$12.9KQUOT
3$36,407$10,561.83$12,123$472.89+$24.3KQUOT
4$53,833$14,878.03$13,141$629.86+$40.7KQUOT
5$78,162$20,560.32$14,408$846.81+$63.8KQUOT
6$111,533$27,899.11$16,021$1,151.60+$95.5KQUOT
7$156,546$37,205.92$18,122$1,588.22+$138.4KQUOT
8$216,309$48,805.40$20,930$2,228.20+$195.4KQUOT
9$294,477$63,025.77$24,792$3,191.91+$269.7KQUOT
10$395,278$80,188.15$30,274$4,689.40+$365.0KQUOT

QUOT vs JNJ: Complete Analysis 2026

QUOTStock

Quotient Technology Inc. operates as a digital media and promotions technology company that offers power integrated digital media and promotions programs for brands and retailers. The company's Quotient Promotions platform offers digital paperless, print promotion, and cash back rebates, including Coupons.com website and mobile applications; brand and retailer websites and mobile applications; and third-party publishing websites and mobile applications. It also provides Quotient Retailer Promotions Platform that uses consumer data and insights to distribute personalized and targeted media and promotions for retailers of grocery, drug, mass merchant, dollar, club, and convenience merchandise; and Quotient Media Platform, which provides targeted advertising solutions that enables brands to reach shoppers before, during, and after their shopping cycles with digital media campaigns. It also provides Quotient Retailer Performance Media Platform that uses retailer's consumer data to drive sales and enhances the shopper experience; Quotient Analytics provides campaign analytics and measured sales results to brands and retailers; Quotient Consumer Properties; and Quotient Retailer Media Services. It serves approximately 900 consumer packed goods, representing approximately 2,500 brands, including various food, beverage, personal care, and household product manufacturers; retail partners representing various classes of trade, such as grocery retailers, drug, mass merchant, dollar, club, and convenience merchandise channels; and consumers visiting its websites, mobile properties, and social channels. The company was formerly known as Coupons.com Incorporated and changed its name to Quotient Technology Inc. in October 2015. Quotient Technology Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Full QUOT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this QUOT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QUOT vs SCHDQUOT vs JEPIQUOT vs OQUOT vs KOQUOT vs MAINQUOT vs ABBVQUOT vs MRKQUOT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.